7
All participants provided written informed consent. This research was approved by the 157
Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam, the Netherlands 158
(reference number MEC-2009-143/NL26508.078.09) , in compliance with the Helsinki 159
Declaration. 160 161

Blood sample analysis 162
Fasting blood samples were obtained from the patients with T2D before and after the 163 20-week dieting period, and from the healthy controls. After centrifugation, plasma 164 samples were stored at -80 o C until analysis. Lipid and glycemic parameters were 165 measured by standard biochemical techniques. Soluble LR11 was measured using a 166 sandwich enzyme-linked immunosorbent assay (ELISA) with two specific monoclonal 167 antibodies against human LR11 (Sekiaui Medical, Ryugasaki Japan) as previously 168 described (30). In brief, 50 µl of plasma diluted with sample buffer were incubated with 169 the capture monoclonal antibody M3 and then incubated with biotinylated reporter 170 monoclonal antibody R14. The LR11-antibody complex was quantitated with 171 horseradish-peroxidase-conjugated streptavidin. A standard curve was constructed 172 using purified LR11 protein. The lower detection limit for sLR11 was 0.1 ng/mL. 173
174
Statistical Analysis 175
This was a post hoc analysis of data obtained in the run-in phase of a randomized trial, 176 with long term weight loss as the primary endpoint (27) . Normality of the data and 177 homogeneity of variances were tested using the Shapiro-Wilks test and Levene's test. 178
Variables before and after the diet intervention period were expressed as ratio (%),8 mean ± standard deviation or median (inter-quartile range). Differences were tested for 180 statistical significance using a two-sided paired samples t-test or a Wilcoxon ranking 181 test, depending on the normality of data. Changes were calculated as value after 182 intervention minus baseline value. Differences between two (sub)groups were tested for 183 significance using either a two-sided t-test or a Mann-Whitney U test. Potential outliers 184
were identified using Cook's Distance statistics (31). Correlations at baseline were 185 determined using Spearman correlation analysis. We performed univariate linear 186 regression analyses to identify potential contributors to the diet-induced changes in 187 sLR11 levels. The change in sLR11 was log transformed to obtain a normal distribution 188 of the residuals of the regression analyses and perform statistical testing. Subsequently, 189 all significant co-variables were included in multivariate analysis. All data were analyzed 190 using IBM SPSS v 21.0 software. 191 193 194 195 Baseline measurements 196
192
Results
The general characteristics of the 64 patients with T2D are shown in Table 1 After a 20-week dietary intervention, the participants lost 10.5 ± 6.1 kg body weight, 221 which was 9.7% (range +1.7% to -20.7%) of the initial body weight (p<0.001, Table 1) . 222
Waist circumference, HDL cholesterol, non-HDL cholesterol, triglyceride, HbA1c, fasting 223 glucose and HOMA-IR all improved significantly (p<0.001). At the end of the diet 224 intervention, the number of participants using insulin was reduced from 45 (70%) to 41 225 (64%; p=0.046), and among insulin users, the median dose was significantly reduced by 226 66 units per day (p<0.001). The number of patients on metformin, statin and ACE 227 inhibitors, and prescribed doses, did not change significantly during the intervention 228
period. 229
After the diet intervention, median plasma sLR11 levels were 13.3 (IQR 11.0-230 17.1) ng/mL, which was significantly lower than baseline levels (p<0.001). The effect of 231 the diet on plasma sLR11 levels varied markedly among the participants, as shown in 232 Figure 1 . Of the 64 participants, 44 exhibited decreased plasma sLR11 levels, 7 233 remained stable (defined as a change below the intra-assay coefficient of variation of 234 3%), and the other 13 participants displayed increased plasma sLR11 levels. The 235 participants with decreased sLR11 levels had lost significantly more weight than the 236 other 20 participants (-11.7 kg vs. -7.7 kg, p=0.009). 237
In Table 2 , the results of the univariate regression analyses with the change in 238 sLR11 are shown. The change in sLR11 was not associated with sex, age and weight 239 loss. Significant associations were observed with change in non-HDL cholesterol 240 In a multiple linear regression model, the change in non-HDL cholesterol and 244
HbA1c remained independently associated with sLR11 change (p=0.003 and p=0.023, 245 The present study shows that plasma sLR11 levels were significantly reduced in 259 overweight and obese individuals with T2D upon a 20-week weight loss diet. The 260 reduction in plasma sLR11 was independently associated with reductions in non-HDL 261 cholesterol and HbA1c, but not with weight loss or the reduction in waist circumference 262 or BMI. The observed reduction in sLR11 during weight loss may have clinical relevance 263 as it is in the same order of magnitude as the previously reported increase in sLR11 264 upon coronary stenting in response to vascular injury (32). Since patients with T2D are 265 prone to develop atherosclerosis, and sLR11 has been shown to facilitate the 266 atherosclerotic process (10, 11, 15, 16) , the reduction in sLR11 may be beneficial in 267 delaying the development of vascular complications. 268
A decrease of sLR11 levels after weight loss has also been described in morbidly 269 obese individuals, who underwent bariatric surgery (17). At 12 months post-surgery, the 270 decrease in sLR11 and BMI was 37 % and 28%, respectively. In our study, 20 weeks of 271 weight loss dieting resulted in a more modest decrease in sLR11 and BMI of 9% and 272 10%, but the decrease in sLR11 relative to that in BMI was similar in both studies. In the 273 bariatric surgery study, the decrease in sLR11 was strongly associated with the loss of 274 adipose tissue mass, but not with the reduction in BMI. In our study, the change in 275 sLR11 levels was also not related to change in BMI, nor with change in weight or waist 276 circumference. However, we did not include measurements of adipose tissue mass. 277
Obviously, the effects of bariatric surgery go beyond weight reduction, and include 278 changes in peptide hormones (like GLP-1 and leptin), bile acid flow and gut bacteria, all 279 potentially affecting sLR11 levels (33). Whether these factors are also affected by diet-280 induced weight loss is unknown. Nonetheless, we show for the first time that the 281 potentially beneficial reduction in sLR11 levels seen after bariatric surgery can also be 282 achieved through weight loss dieting. 283
The average baseline sLR11 level in the overweight and obese subjects with T2D 284 was significantly higher than in healthy, non-obese controls. Comparable high sLR11 285 levels (mean: 16.8 ng/ml) have been reported in morbidly obese individuals (17), 286 suggesting that the high sLR11 level in our participants is related to their prominent 287 obesity. However, in our T2D study group sLR11 levels were not correlated with 288 baseline BMI, weight and waist circumference. Whittle et al. found that circulating sLR11 289 levels were positively correlated with BMI in 156 subjects with sleep apnea and in 25 290 subjects with type 2 diabetes or glucose intolerance (17). The participants in their sleep 291 apnea study group were mostly non-obese, and also in their glucose-intolerant study 292 group half of the participants were non-obese, resulting in a BMI ranging from morbidly 293 obese to underweight values. When we included our healthy, mostly normal weight 294 controls in the analysis, we indeed found a strong correlation between BMI and sLR11. 295
Since this correlation disappeared after correcting for baseline fasting glucose levels, it 296 could be argued that the increase of sLR11 with BMI is secondary to decreased glucose 297 tolerance. In line with this, sLR11 levels have previously been shown to be associated 298 with HbA1c levels in diabetic as well as the non-diabetic patient groups (21, 23, 24) . 299
The mechanism by which sLR11 decreases during weight loss-dieting or bariatric 300 surgery remains to be clarified. There is evidence that circulating sLR11 originates from 301 the vasculature (34); however, brown and white adipose tissue highly express LR11 and 302 therefore may also contribute (17). High-fat feeding significantly increased and fasting 303 decreased LR11 mRNA expression in adipose tissue of mice (17). Similarly, we have 304 previously reported that high-fat feeding upregulates liver LR11 expression and 305 circulating sLR11 levels in mice (18). We have also shown that postprandial TGRL 306 enhance the expression of LR11 in hepatocytes (18), as it does in endothelial cells (35) . 307
Consequently, the decline in sLR11 levels in the overweight subjects with T2D upon 308 dieting may also be due to reduced levels of TGRL during the dieting period. 309 Accordingly, our data show that changes in sLR11 levels associated with changes in 310 non-HDL cholesterol. These changes in non-HDL cholesterol predominantly reflect 311 altered levels of TGRL, because LDL-C levels were hardly affected by the diet (Table 1) . 312
Non-HDL cholesterol level is a known CVD risk factor and a strong predictor of CVD and 313 death in patients with T2D (36, 37). Modulation of sLR11 levels may contribute to the 314 mechanisms by which non-HDL cholesterol affects CVD risk. 315 sLR11 has recently been identified as a negative regulator of brown adipose 316 tissue (BAT) activity (17). It is tempting to speculate that BAT activity increased, possibly 317 contributing to weight loss and improved metabolic profile, as a result of the decreased 318 sLR11 levels in our study population. The association of sLR11 levels with the glycemic 319 state of the participants, as reflected by HbA1c, has been reported previously for the 320 diabetic as well as the non-diabetic population (21, 23, 24) . In mouse models, the 321 increased thermogenic activity in brown and white adipose tissue that is associated with 322 decreased sLR11 levels, has been shown to improve insulin sensitivity and the glycemic 323 state (17). Interestingly, in a recent study mice lacking LR11 expression showed 324 improved insulin sensitivity when fed a high-fat diet, although LR11 was shown to 325 augment insulin receptor signaling in adipocytes by recycling internalized receptor 326 molecules to the cell surface (26). Possibly, the plasma sLR11 levels are only remotely 327 related to LR11 expression in adipose tissue, or the effects of LR11 on systemic glucose 328 tolerance are mainly mediated by circulating sLR11. Alternatively, glucose transporter 329 type 4 (GLUT4)-storage vesicles were found to be enriched in LR11 (38) suggesting a 330 possible role for LR11 in GLUT4 trafficking. Whether sLR11 has a direct effect on 331 glucose metabolism needs further study. 332
333
Study limitations and strengths 334
Diet-induced weight loss induces a wide range of metabolic changes, making it difficult 335
to pinpoint the precise mechanisms responsible for the observed effect on sLR11 levels. 336
Therefore, it remains to be established to which aspect of the dietary intervention the 337 reduction of sLR11 and its associations can be attributed. We did not study the effect on 338 visceral and subcutaneous fat mass, which in part may account for the unexplained 339 variance in sLR11 change. Moreover, we have conducted a before-after study in which 340 we analyzed weight loss in a continuous way. As a consequence, we cannot fully 341 exclude that lifestyle changes other than the dietary intervention have contributed to the 342 weight reduction. Physical activity, however, did not change significantly. Another 343 limitation is the use of change scores in the regression analyses, which may be sensitive 344 to regression toward the mean, although adding baseline levels to the regression 345 analyses did not change our results. Strengths of this study are the prospective design, 346 the relatively large study population of overweight and obese subjects with T2D, and the 347 relatively long duration of the diet intervention. 
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